Effect of oral vitamin D analogs on mortality and cardiovascular outcomes among adults with chronic kidney disease: A meta-analysis

Clinical Kidney Journal

Volumn 8, Issue 1, 2015, Pages 41-48

  Mann, Michelle C ^a   Hobbs, Amy J ^a   Hemmelgarn, Brenda R ^a   Roberts, Derek J ^a   Ahmed, Sofia B ^a   Rabi, Doreen M ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

cardiovascular outcomes; clinical trials; meta analysis; mortality; vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALFACALCIDOL; CALCIUM; COLECALCIFEROL; DOXERCALCIFEROL; PARATHYROID HORMONE; PARICALCITOL; PLACEBO; VITAMIN D DERIVATIVE;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; META ANALYSIS; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PUBLISHING; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 84983160228     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfu122     Document Type: Article

References (40)

1. Go As, Chertow Gm, Fan D et al. Chronic Kidney Disease And The Risks Of Death, Cardiovascular Events, And Hospitalization. N Engl J Med 2004; 351: 1296-1305
2. Petchey Wg, Johnson Dw, Isbel Nm. Shining D' Light On Chronic Kidney Disease: Mechanisms That May Underpin The Cardiovascular Benefit Of Vitamin D. Nephrology 2011; 16: 351-367
3. Gravesen E, Hofman-Bang J, Lewin E et al. Ergocalciferol Treatment And Aspects Of Mineral Homeostasis In Patients With Chronic Kidney Disease Stage 4-5. Scand J Clin Lab Invest 2013; 73: 107-116
4. Forman Jp, Williams Js, Fisher Nd. Plasma 25-Hydroxyvitamin D And Regulation Of The Renin-Angiotensin System In Humans. Hypertension 2010; 55: 1283-1288
5. Galassi A, Antonia B, Auricchio S et al. Which Vitamin D In Ckd-Mbd? The Time Of Burning Questions. Biomed Res Int 2013; 2013: 864012
6. Kandula P, Dobre M, Schold Jd et al. Vitamin D Supplementation In Chronic Kidney Disease: A Systematic Review And Metaanalysis Of Observational Studies And Randomized Controlled Trials. Clin J Am Soc Nephrol 2011; 6: 50-62
7. Thadhani R, Appelbaum E, Pritchett Y et al. Vitamin D Therapy And Cardiac Structure And Function In Patients With Chronic Kidney Disease: The Primo Randomized Controlled Trial. Jama 2012; 307: 674-684
8. Drechsler C, Pilz S, Obermayer-Pietsch B et al. Vitamin D Deficiency Is Associated With Sudden Cardiac Death, Combined Cardiovascular Events, And Mortality In Haemodialysis Patients. Eur Heart J 2010; 31: 2253-2261
9. Quarles Ld. Reducing Cardiovascular Mortality In Chronic Kidney Disease: Something Borrowed, Something New. J Clin Invest 2013; 123: 542-543
10. Zheng Z, Shi H, Jia J et al. Vitamin D Supplementation And Mortality Risk In Chronic Kidney Disease: A Meta-Analysis Of 20 Observational Studies. Bmc Nephrology 2013; 14: 199
11. Bolland Mj, Grey A, Gamble Gd et al. The Effect Of Vitamin D Supplementation On Skeletal, Vascular, Or Cancer Outcomes: A Trial Sequential Meta-Analysis. Lancet Diabet Endocrinol 2014; 2: 307-320
12. Palmer Sc, Mcgregor Do, Craig Jc et al. Vitamin D Compounds For People With Chronic Kidney Disease Not Requiring Dialysis. Cochrane Database Syst Rev 2009; 4: Cd008175
13. Palmer Sc, Mcgregor Do, Craig Jc et al. Vitamin D Compounds For People With Chronic Kidney Disease Requiring Dialysis. Cochrane Database Syst Rev 2009; 4: Cd005633
14. Palmer Sc, Mcgregor Do, Macaskill P et al. Meta-Analysis: Vitamin D Compounds In Chronic Kidney Disease. Ann Int Med 2007; 147: 840-853
15. Theodoratou E, Tzoulaki I, Zgaga L et al. Vitamin D And Multiple Health Outcomes: Umbrella Review Of Systematic Reviews And Meta-Analyses Of Observational Studies And Randomised Trials. Bmj 2014; 348: G2035
16. Moher D, Liberati A, Tetzlaff J et al. Preferred Reporting Items For Systematic Reviews And Meta-Analyses: The Prisma Statement. Open Med 2010; 3: E123-E130
17. Higgins Jp, Altman Dg, Gotzsche Pc et al. The Cochrane Collaboration's Tool For Assessing Risk Of Bias In Randomised Trials. Bmj 2011; 343: D5928
18. Dersimonian R, Laird N. Meta-Analysis In Clinical Trials. Control Clin Trials 1986; 7: 177-188
19. Alvarez Ja, Law J, Coakley Ke et al. High-Dose Cholecalciferol Reduces Parathyroid Hormone In Patients With Early Chronic Kidney Disease: A Pilot, Randomized, Double-Blind, Placebocontrolled Trial. Am J Clin Nutr 2012; 96: 672-679
20. Coburn Jw, Maung Hm, Elangovan L et al. Doxercalciferol Safely Suppresses Pth Levels In Patients With Secondary Hyperparathyroidism Associated With Chronic Kidney Disease Stages 3 And 4. Am J Kidney Dis 2004; 43: 877-890
21. Coyne D, Acharya M, Qiu P et al. Paricalcitol Capsule For The Treatment Of Secondary Hyperparathyroidism In Stages 3 And 4 Ckd. Am J Kidney Dis 2006; 47: 263-276
22. De Zeeuw D, Agarwal R, Amdahl M et al. Selective Vitamin D Receptor Activation With Paricalcitol For Reduction Of Albuminuria In Patients With Type 2 Diabetes (Vital Study): A Randomised Controlled Trial. Lancet 2010; 376: 1543-1551
23. Delanaye P, Weekers L, Warling X et al. Cholecalciferol In Haemodialysis Patients: A Randomized, Double-Blind, Proofof-Concept And Safety Study. Nephrol Dial Transplant 2013; 28: 1779-1786
24. Frazao Jm, Elangovan L, Maung Hm et al. Intermittent Doxercalciferol (1Alpha-Hydroxyvitamin D(2)) Therapy For Secondary Hyperparathyroidism. Am J Kidney Dis 2000; 36: 550-561
25. Hamdy Na, Kanis Ja, Beneton Mn et al. Effect Of Alfacalcidol On Natural Course Of Renal Bone Disease In Mild To Moderate Renal Failure. Bmj 1995; 310: 358-363
26. Hewitt Na, O'connor Aa, O'shaughnessy Dv et al. Effects Of Cholecalciferol On Functional, Biochemical, Vascular, And Quality Of Life Outcomes In Hemodialysis Patients. Clin J Am Soc Nephrol 2013; 8: 1143-1149
27. Marckmann P, Agerskov H, Thineshkumar S et al. Randomized Controlled Trial Of Cholecalciferol Supplementation In Chronic Kidney Disease Patients With Hypovitaminosis D. Nephrol Dial Transplant 2012; 27: 3523-3531
28. Memmos De, Eastwood Jb, Talner Lb et al. Double-Blind Trial Of Oral 1,25-Dihydroxy Vitamin D3 Versus Placebo In Asymptomatic Hyperparathyroidism In Patients Receiving Maintenance Haemodialysis. Br Med J Clin Res Ed 1981; 282: 1919-1924
29. Wang Ay, Fang F, Chan J et al. Effect Of Paricalcitol On Left Ventricular Mass And Function In Ckd-The Opera Trial. J Am Soc Nephrol 2014; 25: 175-186
30. Wasse H, Huang R, Long Q et al. Efficacy And Safety Of A Short Course Of Very-High-Dose Cholecalciferol In Hemodialysis. Am J Clin Nutr 2012; 95: 522-528
31. National Kidney F. K/Doqi Clinical Practice Guidelines For Chronic Kidney Disease: Evaluation, Classification, And Stratification. Am J Kid Dis 2002; 39(2 Suppl 1): S1-266
32. Coyne Dw, Andress Dl, Amdahl Mj et al. Effects Of Paricalcitol On Calcium And Phosphate Metabolism And Markers Of Bone Health In Patients With Diabetic Nephropathy: Results Of The Vital Study. Nephrol Dial Transplant 2013; 28: 2260-2268
33. Nigwekar Su, Bhan I, Thadhani R. Ergocalciferol And Cholecalciferol In Ckd. Am J Kidney Dis 2012; 60: 139-156
34. Vieth R. Why Vitamin D" Is Not A Hormone, And Not A Synonym For 1,25-Dihydroxy-Vitamin D, Its Analogs Or Deltanoids. J Steroid Biochem Mol Biol 2004; 89-90: 571-573
35. Melamed Ml, Thadhani Ri. Vitamin D Therapy In Chronic Kidney Disease And End Stage Renal Disease. Clin J Am Soc Nephrol 2012; 7: 358-365
36. Scragg Rkr, Kenealy T, Bryant Ljm et al. Vitamin D For Preventing Cardiovascular Disease. Cochrane Database Syst Rev 2013; 1: Cd008967
37. Ranpuria R, Hall M, Chan Ct et al. Heart Rate Variability (Hrv) In Kidney Failure: Measurement And Consequences Of Reduced Hrv. Nephrol Dial Transplant 2008; 23: 444-449
38. Mannmc, Hemmelgarn Br, Turin Tcet Al. Vitamin D Supplementation Is Associated With Improved Modulation Of Cardiac Autonomic Tone In Healthy Humans. Int J Cardiol 2013; 172: 506-508
39. Thayer Jf, Yamamoto Ss, Brosschot Jf. The Relationship Of Autonomic Imbalance, Heart Rate Variability, And Cardiovascular Disease Risk Factors. Int J Cardiol 2010; 141: 122-131
40. Wolf M, Betancourt J, Chang Y et al. Impact Of Activated Vitamin D And Race On Survival Among Hemodialysis Patients. J Am Soc Nephrol 2008; 19: 1379-1388